| Drug General Information |
| Drug ID |
D0T6JO
|
| Former ID |
DNC012054
|
| Drug Name |
Indol-1-yl-propyl-pyridin-4-yl-amine
|
| Synonyms |
Indol-1-yl-propyl-pyridin-4-yl-amine (Besipirdine)
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Canonical SMILES |
CCCN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32
|
| InChI |
1S/C16H17N3/c1-2-12-18(15-7-10-17-11-8-15)19-13-9-14-5-3-4-6-16(14)19/h3-11,13H,2,12H2,1H3
|
| InChIKey |
OTPPJICEBWOCKD-UHFFFAOYSA-N
|
| Target and Pathway |
| Target(s) |
Alpha-2A adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Sodium channel protein type 5 subunit alpha |
Target Info |
Inhibitor |
[2]
|
| Alpha-2B adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
| Sodium channel |
Target Info |
Inhibitor |
[2]
|
| Alpha-2C adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04261:Adrenergic signaling in cardiomyocyteshsa04022:cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04728:Dopaminergic synapsehsa04022:cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
PathWhiz Pathway
|
Muscle/Heart Contraction
|
|
Reactome
|
Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling events
|
|
Surfactant metabolismR-HSA-445095:Interaction between L1 and AnkyrinsR-HSA-390696:Adrenoceptors
|
|
G alpha (z) signalling eventsR-HSA-445095:Interaction between L1 and AnkyrinsR-HSA-390696:Adrenoceptors
|
|
Surfactant metabolism
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Platelet Aggregation (Plug Formation)
|
|
Integration of energy metabolism
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP706:SIDS Susceptibility Pathways
|
|
Cardiac Progenitor DifferentiationWP58:Monoamine GPCRs
|
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
|
GPCR downstream signaling
|
| References |
| REF 1 | J Med Chem. 1996 Jan 19;39(2):570-81.Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease. |
|---|
| REF 2 | J Med Chem. 2001 Jan 18;44(2):115-37.Medicinal chemistry of neuronal voltage-gated sodium channel blockers. |
|---|
